NFSG Corp Purchases 1,497 Shares of Cencora, Inc. $COR

NFSG Corp lifted its position in shares of Cencora, Inc. (NYSE:COR) by 14,970.0% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,507 shares of the company’s stock after buying an additional 1,497 shares during the period. NFSG Corp’s holdings in Cencora were worth $452,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Deutsche Bank AG bought a new position in Cencora during the second quarter valued at approximately $286,673,000. Impact Partnership Wealth LLC purchased a new position in shares of Cencora during the first quarter worth approximately $1,170,000. SEB Asset Management AB bought a new stake in shares of Cencora in the 1st quarter worth approximately $134,139,000. Wedge Capital Management L L P NC lifted its holdings in shares of Cencora by 31.0% in the 2nd quarter. Wedge Capital Management L L P NC now owns 105,614 shares of the company’s stock worth $29,887,000 after acquiring an additional 24,968 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new position in Cencora in the 2nd quarter worth $841,000. Institutional investors own 97.52% of the company’s stock.

Insider Buying and Selling at Cencora

In other news, EVP Elizabeth Campbell sold 11,300 shares of Cencora stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $324.12, for a total value of $3,662,556.00. Following the sale, the executive vice president directly owned 19,455 shares in the company, valued at approximately $6,305,754.60. This trade represents a 36.74% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.38% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently weighed in on COR. UBS Group lowered their target price on Cencora from $430.00 to $400.00 and set a “buy” rating for the company in a research note on Friday. Evercore restated an “outperform” rating and issued a $350.00 target price (up from $330.00) on shares of Cencora in a report on Thursday, August 6th. JPMorgan Chase & Co. lifted their target price on shares of Cencora from $382.00 to $390.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. Leerink Partners upped their price target on shares of Cencora from $380.00 to $388.00 and gave the company an “outperform” rating in a report on Wednesday, October 7th. Finally, Royal Bank Of Canada reissued a “sector perform” rating and set a $330.00 price target on shares of Cencora in a research report on Tuesday, September 8th. Fourteen research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $363.81.

Cencora Trading Down 0.3%

Shares of NYSE COR traded down $0.87 during trading hours on Friday, hitting $340.54. The company’s stock had a trading volume of 1,978,868 shares, compared to its average volume of 1,282,490. The company has a debt-to-equity ratio of 3.53, a quick ratio of 0.58 and a current ratio of 0.93. The stock has a market cap of $64.99 billion, a price-to-earnings ratio of 25.30, a P/E/G ratio of 1.75 and a beta of 0.58. Cencora, Inc. has a 12 month low of $244.82 and a 12 month high of $377.54. The business has a 50-day simple moving average of $320.38 and a 200-day simple moving average of $303.34.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $4.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.35 by $0.13. The company had revenue of $84.75 billion for the quarter, compared to the consensus estimate of $84.31 billion. Cencora had a return on equity of 125.45% and a net margin of 0.79%. Cencora’s revenue was up 5.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $4.00 EPS. On average, analysts anticipate that Cencora, Inc. will post 17.87 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 31st. Stockholders of record on Friday, August 14th were given a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date was Friday, August 14th. Cencora’s dividend payout ratio (DPR) is currently 17.83%.

Cencora Profile

Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical solutions company that sources, distributes and supports the delivery of medicines and healthcare products. The company serves pharmaceutical manufacturers, healthcare providers, pharmacies and animal-health customers through its supply-chain and commercialization services.

Its activities include pharmaceutical and specialty-product distribution, manufacturer services, specialty logistics, clinical-trial support, patient-support programs and other services designed to help bring medicines to market and improve access to treatment.